455 related articles for article (PubMed ID: 15961591)
1. Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination.
Trotter CL; Gay NJ; Edmunds WJ
Am J Epidemiol; 2005 Jul; 162(1):89-100. PubMed ID: 15961591
[TBL] [Abstract][Full Text] [Related]
2. Reassessing the cost-effectiveness of meningococcal serogroup C conjugate (MCC) vaccines using a transmission dynamic model.
Trotter CL; Edmunds WJ
Med Decis Making; 2006; 26(1):38-47. PubMed ID: 16495199
[TBL] [Abstract][Full Text] [Related]
3. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States.
Ortega-Sanchez IR; Meltzer MI; Shepard C; Zell E; Messonnier ML; Bilukha O; Zhang X; Stephens DS; Messonnier NE;
Clin Infect Dis; 2008 Jan; 46(1):1-13. PubMed ID: 18171206
[TBL] [Abstract][Full Text] [Related]
4. Carriage of Neisseria meningitidis in Europe: a review of studies undertaken in the region.
Soriano-Gabarró M; Wolter J; Hogea C; Vyse A
Expert Rev Anti Infect Ther; 2011 Sep; 9(9):761-74. PubMed ID: 21905785
[TBL] [Abstract][Full Text] [Related]
5. Rapid identification of herd effects with the introduction of serogroup C meningococcal conjugate vaccine in Ontario, Canada, 2000-2006.
Kinlin LM; Jamieson F; Brown EM; Brown S; Rawte P; Dolman S; Drews SJ; Fisman DN
Vaccine; 2009 Mar; 27(11):1735-40. PubMed ID: 19186206
[TBL] [Abstract][Full Text] [Related]
6. Expanding prevention of invasive meningococcal disease.
Pelton SI; Gilmet GP
Expert Rev Vaccines; 2009 Jun; 8(6):717-27. PubMed ID: 19485753
[TBL] [Abstract][Full Text] [Related]
7. Invasive meningococcal disease epidemiology and control measures: a framework for evaluation.
Caro JJ; Möller J; Getsios D; Coudeville L; El-Hadi W; Chevat C; Nguyen VH; Caro I
BMC Public Health; 2007 Jun; 7():130. PubMed ID: 17603880
[TBL] [Abstract][Full Text] [Related]
8. Optimising the use of conjugate vaccines to prevent disease caused by Haemophilus influenzae type b, Neisseria meningitidis and Streptococcus pneumoniae.
Trotter CL; McVernon J; Ramsay ME; Whitney CG; Mulholland EK; Goldblatt D; Hombach J; Kieny MP;
Vaccine; 2008 Aug; 26(35):4434-45. PubMed ID: 18617296
[TBL] [Abstract][Full Text] [Related]
9. Challenges for development of meningococcal vaccines in infants and children.
Deasy A; Read RC
Expert Rev Vaccines; 2011 Mar; 10(3):335-43. PubMed ID: 21434801
[TBL] [Abstract][Full Text] [Related]
10. Immunologic memory 5 years after meningococcal A/C conjugate vaccination in infancy.
MacLennan J; Obaro S; Deeks J; Lake D; Elie C; Carlone G; Moxon ER; Greenwood B
J Infect Dis; 2001 Jan; 183(1):97-104. PubMed ID: 11087205
[TBL] [Abstract][Full Text] [Related]
11. Prevention of meningococcal disease: current use of polysaccharide and conjugate vaccines.
Poland GA
Clin Infect Dis; 2010 Mar; 50 Suppl 2():S45-53. PubMed ID: 20144016
[TBL] [Abstract][Full Text] [Related]
12. The Meningitis Vaccine Project.
LaForce FM; Konde K; Viviani S; Préziosi MP
Vaccine; 2007 Sep; 25 Suppl 1():A97-100. PubMed ID: 17521780
[TBL] [Abstract][Full Text] [Related]
13. Neisseria meningitidis B vaccines.
Panatto D; Amicizia D; Lai PL; Gasparini R
Expert Rev Vaccines; 2011 Sep; 10(9):1337-51. PubMed ID: 21919622
[TBL] [Abstract][Full Text] [Related]
14. Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity.
Kristiansen PA; Diomandé F; Ba AK; Sanou I; Ouédraogo AS; Ouédraogo R; Sangaré L; Kandolo D; Aké F; Saga IM; Clark TA; Misegades L; Martin SW; Thomas JD; Tiendrebeogo SR; Hassan-King M; Djingarey MH; Messonnier NE; Préziosi MP; Laforce FM; Caugant DA
Clin Infect Dis; 2013 Feb; 56(3):354-63. PubMed ID: 23087396
[TBL] [Abstract][Full Text] [Related]
15. [Meningococcal disease in the Netherlands: media hype, but not an epidemic].
van Furth AM; Zaaijer HL
Ned Tijdschr Geneeskd; 2001 Sep; 145(36):1716-8. PubMed ID: 11572168
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of serogroup A meningococcal vaccines in Africa: a demonstration project.
Soriano-Gabarró M; Rosenstein N; LaForce FM
J Health Popul Nutr; 2004 Sep; 22(3):275-85. PubMed ID: 15609780
[TBL] [Abstract][Full Text] [Related]
17. Long-term protection in children with meningococcal C conjugate vaccination: lessons learned.
Borrow R; Miller E
Expert Rev Vaccines; 2006 Dec; 5(6):851-7. PubMed ID: 17184222
[TBL] [Abstract][Full Text] [Related]
18. Meningococcal C conjugate vaccine: the experience in England and Wales.
Campbell H; Borrow R; Salisbury D; Miller E
Vaccine; 2009 Jun; 27 Suppl 2():B20-9. PubMed ID: 19477053
[TBL] [Abstract][Full Text] [Related]
19. Quadrivalent meningococcal conjugate vaccines.
Pace D; Pollard AJ; Messonier NE
Vaccine; 2009 Jun; 27 Suppl 2():B30-41. PubMed ID: 19477560
[TBL] [Abstract][Full Text] [Related]
20. Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in The Netherlands and its impact on decision-making.
Welte R; van den Dobbelsteen G; Bos JM; de Melker H; van Alphen L; Spanjaard L; Rümke HC; Postma MJ
Vaccine; 2004 Dec; 23(4):470-9. PubMed ID: 15530695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
